ConductScience.org, home

Paper41545871

Activation of the pituitary adenylate cyclase-activating polypeptide type I receptor promotes neuroblastoma proliferation and migration through distinct G protein pathways.

Jang S and 2 others. Cell Commun Signal, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Activation of the pituitary adenylate cyclase-activating polypeptide type I receptor promotes neuroblastoma proliferation and migration through distinct G protein pathways. Papers, record 41545871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41545871

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activation of the pituitary adenylate cyclase-activating polypeptide type I receptor promotes neuroblastoma proliferation and migration through distinct G protein pathways.
PubMed
Journal
Cell Commun Signal
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-06-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jang SSarah
2Jeong JYJae-Yeon
3Huh WKWon-Ki

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeuroblastomaMajor topic
Cell MovementMajor topic
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IMajor topic
Signal TransductionMajor topic
GTP-Binding ProteinsMajor topic
Cell Proliferation
Humans
Cell Line, Tumor
Pituitary Adenylate Cyclase-Activating Polypeptide

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
RS-2020-NR049538National Research Foundation of KoreaPubMed

Source PubMed

Download CSV of grants

References83

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130088106PACAP38 and PAC1 receptor blockade: a new target for headache?J Headache Pain2018https://conductscience.org/library/papers/30088106PubMed
228966937Origin and mechanism of neuroblastoma.Oncoscience2017https://conductscience.org/library/papers/28966937PubMed
316226889Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.Mol Cell Neurosci2006https://conductscience.org/library/papers/16226889PubMed
411166697Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.Brain Res2001https://conductscience.org/library/papers/11166697PubMed
529246327In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR/Cas9 in Mouse Retinal Pigment Epithelium Cells.Mol Ther Nucleic Acids2017https://conductscience.org/library/papers/29246327PubMed
617651798
The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
Cell Calcium2008https://conductscience.org/library/papers/17651798PubMed
719109992VPAC and PAC receptors: From ligands to function.Pharmacol Ther2009https://conductscience.org/library/papers/19109992PubMed
823517078VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.Br J Pharmacol2013https://conductscience.org/library/papers/23517078PubMed
935897648Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.Int J Mol Sci2022https://conductscience.org/library/papers/35897648PubMed
102383262Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38).Biochem Biophys Res Commun1990https://conductscience.org/library/papers/2383262PubMed
1120879880Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.N Engl J Med2010https://conductscience.org/library/papers/20879880PubMed
1222529259Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.J Clin Oncol2012https://conductscience.org/library/papers/22529259PubMed
1335053757The PACAP/PAC1 Receptor System and Feeding.Brain Sci2021https://conductscience.org/library/papers/35053757PubMed
1431284862Targeting the PAC1 Receptor for Neurological and Metabolic Disorders.Curr Top Med Chem2019https://conductscience.org/library/papers/31284862PubMed
1522389426Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.J Pharmacol Exp Ther2012https://conductscience.org/library/papers/22389426PubMed
1635302493Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs.Elife2022https://conductscience.org/library/papers/35302493PubMed
1728692064Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.Nat Med2017https://conductscience.org/library/papers/28692064PubMed
1822532442Signaling through the neuropeptide GPCR PAC₁ induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor.FASEB J2012https://conductscience.org/library/papers/22532442PubMed
1929298813G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?Mol Pharmacol2018https://conductscience.org/library/papers/29298813PubMed
2012880962Genetic and epigenetic alterations in neuroblastoma.Cancer Lett2003https://conductscience.org/library/papers/12880962PubMed

See all 83 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42862439Pituitary adenomas (PitNETs): molecular pathophysiology, targeted drug delivery strategies and clinical therapeutic outcomes.Mol Biol Rep2026https://conductscience.org/library/papers/42862439PubMed
42346154PACAP and Maxadilan (PAC1 Agonist) Influence Plaque Progression, Migratory Ability, and Mitochondrial Morphology and Dynamics in Vascular Smooth Muscle Cells.Cells2026https://conductscience.org/library/papers/42346154PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ADCYAP1R1117PubTator's text mininghttps://conductscience.org/library/genes/117

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41545871

GET https://conductscience.org/api/papers/v1/41545871/references?page=2